The Chinese Environmental Protection Bureau has issued Siegfried Group the final operating approval for its Nantong production site for active pharmaceutical ingredients. Consequently, all approvals and certificates required by the authorities for large-scale production have now been obtained. Trial operation for the commercial facilities had started a year ago.

Siegfried's Nantong production site is located in an industrial park northwest of Shanghai. The site's production capacity amounts to 350 cubic meters and provides work for about 200 employees. The facility was inaugurated in August 2015. The pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.

The Nantong site is one of several recent expansions for Siegfried. In 2015 it acquired BASF's pharmaceutical supply business and the corresponding three sites in Evionnaz, Switzerland, Saint-Vulbas, France, and Minden, Germany. The three sites with more than 800 employees reported total sales for 2014 of approximately CHF 280 million ($316 million). That acquisition represents the final step in Siegfried's targeted acquisition policy implemented over the past several years. Siegfried previously acquired California-based AMP and Hameln Pharma in Hameln, Germany.

Source: Siegfried